Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".
Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".
复制标题
DOI：
10.1002/npr2.12193
复制
发表时间：
2021-09
影响因子：
2.5
通讯作者：
Japanese Society of Neuropsychopharmacology
中科院分区：
文献类型：
--
作者：
Japanese Society of Neuropsychopharmacology
精神分裂症治疗指南已经在不同的国家制定，并在日本被翻译和使用。然而，日本和其他国家的可用药物及其管理和医疗系统可能会有所不同。因此，需要一种与日本的医疗情况相一致的临床指南。日本以前有过依赖专家意见的临床指南，但没有一个是基于科学证据的。出于这个原因，需要一份临床指南，收集迄今为止所获得的发现，并以科学证据为基础。考虑到这一点，日本神经精神药理学学会成立了一个精神分裂症药物治疗指南工作组，并制定了该指南。应该再次指出，精神分裂症的治疗不仅仅是基于药物治疗。全面的治疗，如心理社会治疗和与医疗福利的合作是必要的。不言而喻，制定一个全面的治疗指南是可取的，但我们已经决定制定一个有相对充足证据的药物治疗指南，作为创建一个全面指南的第一步。日本精神分裂症研究学会的成员也参与了这份指南的制定，并主要负责撰写导言中的“阅读本指南前”部分。
Guidelines for schizophrenia treatment have been created in various countries and have been translated and used in Japan as well. However, the available drugs and their administration and the medical system can vary between Japan and other countries. Therefore, a clinical guideline that is aligned with the medical circumstances in Japan was needed. There have been previous clinical guidelines in Japan that relied on expert opinion, but there are none based on scientific evidence. For this reason, a clinical guideline that gathers the findings obtained to date and is based on scientific evidence was needed. With this in mind, the Japanese Society of Neuropsychopharmacology formed a Task Force of Guideline for Pharmacological Therapy of Schizophrenia and create the guideline. It should be stated once again that schizophrenia treatment is not based on pharmacological therapy alone. Comprehensive treatment such as psychosocial therapy and collaborations with medical welfare is necessary. It is self-evident that creating a comprehensive treatment guideline is desirable, but we have decided to create a guideline for pharmacological therapy for which there is relatively ample evidence as a first step for the creation of a comprehensive guideline. Members of the Japanese Society for Schizophrenia Research also participated in the creation of this guideline and were mainly in charge of writing the “Before reading this guideline” section in the introduction.
登录
查看更多内容
影响因子：
8.4
作者：
Asenjo Lobos, Claudia;Komossa, Katja;Rummel-Kluge, Christine;Hunger, Heike;Schmid, Franziska;Schwarz, Sandra;Leucht, Stefan
通讯作者：
Leucht, Stefan
影响因子：
4.1
作者：
Afshar, H.;Roohafza, H.;Talaei, M.
通讯作者：
Talaei, M.
影响因子：
5.3
作者：
Addington, Donald E.;Mohamed, Somaia;Lieberman, Jeffrey A.
通讯作者：
Lieberman, Jeffrey A.
影响因子：
5.3
作者：
Agid, Ofer;Arenovich, Tamara;Remington, Gary
通讯作者：
Remington, Gary
影响因子：
5.3
作者：
Addington, DEN;Pantelis, C;Romano, SJ
通讯作者：
Romano, SJ